Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
The following section summarizes insights on undefined's Net Income to Common Excl Extra Items:
We've identified the following companies as similar to Aequus Pharmaceuticals Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
| Name | Ticker | Net Income to Common Excl Extra Items |
|---|---|---|
| Red White & Bloom Brands Inc | CNSX:RWB | -128.3 M |
| Numinus Wellness Inc | TSX:NUMI | -25.506 M |
| Pharmacielo Ltd | TSXV:PCLO | -9.141 M |
| Aion Therapeutic Inc | CNSX:AION | -6.731 M |
| BioNxt Solutions Inc | CNSX:BNXT | -6.479 M |
| Mountain Valley MD Holdings Inc | CNSX:MVMD | -4.009 M |
| Aequus Pharmaceuticals Inc | TSXV:AQS | -2.676 M |
| Healthcare | SECTOR:HLTH.CA | -2.472 M |
| Herbal Dispatch Inc | CNSX:HERB | -1.578 M |
| CordovaCann Corp | CNSX:CDVA | -828.105 K |
| CanadaBis Capital Inc | TSXV:CANB | 201.753 K |
| Grey Wolf Animal Health Corp | TSXV:WOLF | 921.888 K |
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Net Income to Common Excl Extra Items in the popular category include:
Represents the net income or loss available to common stockholders and is arrived after adjusting preferred stock dividends and other adjustments to n...
Aequus Pharmaceuticals reported net income to common excl extra items of -2.676 M for the latest twelve months ending September 30, 2024 on its income statement.
The tables below summarizes Aequus Pharmaceuticals’s Net Income to Common Excl Extra Items and common size over the last five years:
| Fiscal Year | Net Income to Common Excl Extra Items | Revenue | % Revenue |
|---|---|---|---|
| 2019-12-31 | -3.106 M | 1.633 M | −190.3% |
| 2020-12-31 | -1.045 M | 2.593 M | −40.3% |
| 2021-12-31 | -1.81 M | 2.715 M | −66.7% |
| 2022-12-31 | -3.21 M | 1.38 M | −232.7% |
| 2023-12-31 | -2.965 M | 254.896 T | −1,163.1% |
The tables below summarizes Aequus Pharmaceuticals’s Net Income to Common Excl Extra Items and common size over the last four quarters:
| Quarter Ending | Net Income to Common Excl Extra Items | Revenue | % Revenue |
|---|---|---|---|
| 2023-12-31 | -715.87 T | 50.877 T | −1,407.1% |
| 2024-03-31 | -662.088 T | 52.555 T | −1,259.8% |
| 2024-06-30 | -683.033 T | 161.413 T | −423.2% |
| 2024-09-30 | -614.731 T | 148.32 T | −414.5% |
The chart above depicts the distribution of Net Income to Common Excl Extra Items for companies operating in the Healthcare Sector in the Developed economic region. Over 2,500 companies were considered in this analysis, and 2,406 had meaningful values. The average Net Income to Common Excl Extra Items of companies in the Sector is -1.462 M with a standard deviation of 213.1 M. Please note that Sector and Industry values may differ from other sources, as no adjustments have been made.
Aequus Pharmaceuticals Inc's Net Income to Common Excl Extra Items of -2.676 M ranks in the 62.0% percentile for the Sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,506 |
| Included Constituents | 2,406 |
| Min | -535 M |
| Max | 1.901 B |
| Median | -7.788 M |
| Mean | -1.462 M |
| Standard Deviation | 213.1 M |
You can find companies with similar Net Income to Common Excl Extra Items using this stock screener.
The video below provides an overview of the key benefits to help you get the most out of InvestingPro.